We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Astaxanthin Supplementation in Cyclists

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01241877
Recruitment Status : Unknown
Verified April 2011 by Maastricht University Medical Center.
Recruitment status was:  Recruiting
First Posted : November 16, 2010
Last Update Posted : April 20, 2011
Information provided by:
Maastricht University Medical Center

Brief Summary:

Background of the study:

Astaxanthin has been shown to be a powerfull anti-oxidant. Health benefits have been shown in animals and humans. Exercise enhancing effects have been shown in animals via enhancement of fat oxidation. We want to examine the effects of 4 weeks of astaxanthin supplementation on fat oxidation and cycling performance in trained cyclists

Objective of the study:

To test the hypothesis that 4 weeks supplementation with astaxanthin will improve fat oxidation and improve exercise performance in trained cyclists

Study design:

Double blind, placebo controlled study.

Study population:

Well trained cyclists between 18-30 years old

Intervention (if applicable):

astaxanthin (20 mg/day) or placebo for 4 weeks

Primary study parameters/outcome of the study:

performance on a time trial after 90 min steady state exercise.

Secundary study parameters/outcome of the study (if applicable):

substrate use plasma glucose plasma lactate plasma free fatty acid plasma astaxanthin

Nature and extent of the burden and risks associated with participation, benefit and group relatedness (if applicable):

The risks involved in participating in this experiment are minimal. Astaxanthin has been shown to be safe. Insertion of the catheters in a vein is comparable to a normal blood draw and the only risk is of a small local haematoma.

Condition or disease Intervention/treatment
Athletic Performance Dietary Supplement: astaxanthin Dietary Supplement: placebo

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Study Start Date : November 2010
Estimated Primary Completion Date : June 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Astaxanthin
U.S. FDA Resources

Arm Intervention/treatment
Experimental: astaxanthin Dietary Supplement: astaxanthin
Placebo Comparator: placebo Dietary Supplement: placebo

Primary Outcome Measures :
  1. time trial performance [ Time Frame: 4 weeks ]
    time trial performance

Secondary Outcome Measures :
  1. substrate use [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy
  • Male
  • Age between 18 and 30 years
  • Endurance trained (≥3 sessions of endurance exercise per week)
  • VO2 max ≥ 50 ml/kg/min
  • Training history of more than one year of ≥3 sessions of endurance exercise per week
  • BMI <25 kg/m2

Exclusion Criteria:

  • Use of medication
  • Smoking

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01241877

Contact: Peter Res, MSc +3143381383 peter.res@maastrichtuniversity.nl

Maastricht University Recruiting
Maastricht, LI, Netherlands, 6229
Contact: Peter Res, MSc    +3143381383    peter.res@maastrichtuniversity.nl   
Sponsors and Collaborators
Maastricht University Medical Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Peter Res, MUMC
ClinicalTrials.gov Identifier: NCT01241877     History of Changes
Other Study ID Numbers: MEC 10-3-068
First Posted: November 16, 2010    Key Record Dates
Last Update Posted: April 20, 2011
Last Verified: April 2011